Zhitong Finance App News, Shiyao Group (01093.HK) announced that the GLP-1/GIP receptor bidirectional agonist peptide injection (SYH2069 injection) (this product) developed by the Group has been approved by the US Food and Drug Administration (FDA) and can conduct clinical trials in the US.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Shiyao Group (01093.HK) announced that the GLP-1/GIP receptor bidirectional agonist peptide injection (SYH2069 injection) (this product) developed by the Group has been approved by the US Food and Drug Administration (FDA) and can conduct clinical trials in the US.